Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurological Sciences
Published in: Neurological Sciences 7/2022

14-04-2022 | Migraine | Letter to the Editor

Increase in CGRP levels in a case of hemicrania continua normalizes after a successful response to galcanezumab

Authors: Gabriel Gárate, Sara Pérez Pereda, Vicente González-Quintanilla, Jorge Madera, Julio Pascual

Published in: Neurological Sciences | Issue 7/2022

Login to get access

Excerpt

A few months ago, we reported in Neurological Sciences the first case of hemicrania continua clearly responsive to galcanezumab, one of the CGRP monoclonal antibodies [1]. As in all primary headaches, however, it is impossible to be absolutely sure that the response to a given treatment is real or if it is related to a placebo effect. …
Literature
1.
González-Quintanilla V, Pérez-Pereda S, Fontanillas N, Pascual J (2021) First case of hemicrania continua responsive to galcanezumab. Neurol Sci 42:4775–4665CrossRef
2.
Giani L, Proietti Cecchini A, Leone M (2020) Cluster headache and TACs: state of the art. Neurol Sci 41(Suppl 2):376–475
3.
Pozo-Rosich P, Coppola G, Pascual J, Schwedt TJ (2021) How does the brain change in chronic migraine? Developing disease biomarkers. Cephalalgia 41:613–630CrossRef
Metadata
Title
Increase in CGRP levels in a case of hemicrania continua normalizes after a successful response to galcanezumab
Authors
Gabriel Gárate
Sara Pérez Pereda
Vicente González-Quintanilla
Jorge Madera
Julio Pascual
Publication date
14-04-2022
Publisher
Springer International Publishing
Published in
Neurological Sciences / Issue 7/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-022-06063-2

Other articles of this Issue 7/2022

Neurological Sciences 7/2022 Go to the issue

COVID-19

Bilateral facial palsy after COVID-19 vaccination

Original Article

Effect of convergence on the horizontal VOR in normal subjects and patients with peripheral and central vestibulopathy

Original Article

Clinical, genetic, and pathological characterization of GNE myopathy in China

Original Article

Psychoeducational groups for people with Amyotrophic Lateral Sclerosis and their caregiver: a qualitative study

Original Article

The altered multiscale dynamics of spontaneous brain activity in depression with Parkinson’s disease

COVID-19

Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab